Boothbay Fund Management’s CytomX Therapeutics CTMX Stock Holding History

Boothbay Fund Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.3K	Hold	15,000	–	–	﹤0.01%	2092
2026 Q1	$70.5K	Sell	15,000 -879,663	-98%	-$4.47M	﹤0.01%	1897
2025 Q4	$3.81M	Sell	894,663 -342,394	-28%	-$1.3M	0.06%	372
2025 Q3	$3.95M	Buy	+1,237,057	New	+$2.79M	0.06%	375
2022 Q3	–	Sell	-20,054	Closed	-$37K	–	2299
2022 Q2	$37K	Buy	20,054 +6,953	+53%	+$13.3K	﹤0.01%	2110
2022 Q1	$35K	Buy	+13,101	New	+$50.3K	﹤0.01%	2212
2021 Q3	–	Sell	-15,182	Closed	-$96K	–	1943
2021 Q2	$96K	Sell	15,182 -80,102	-84%	-$624K	﹤0.01%	1745
2021 Q1	$737K	Buy	+95,284	New	+$754K	0.03%	743
2020 Q3	–	Sell	-14,595	Closed	-$122K	–	1072
2020 Q2	$122K	Buy	14,595 +695	+5%	+$6.45K	0.01%	858
2020 Q1	$107K	Buy	+13,900	New	+$96.9K	0.01%	720
2019 Q1	–	Sell	-10,000	Closed	-$151K	–	774
2018 Q4	$151K	Buy	+10,000	New	+$148K	0.02%	515

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Boothbay Fund Management's CTMX Position: Q2 2026 in Review

Boothbay Fund Management held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 15,000 shares worth $56.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2092.

Boothbay Fund Management first reported a position in CTMX in Q4 2018 and has held it in 11 quarters since. The position peaked at $3.95M in Q3 2025. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Boothbay Fund Management held 15,000 shares of CytomX Therapeutics worth $56.3K as of Q2 2026.
Boothbay Fund Management left its CytomX Therapeutics share count unchanged in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2092 holding.
Boothbay Fund Management first reported a position in CytomX Therapeutics in Q4 2018 and has held it in 11 quarters since.
Boothbay Fund Management's CytomX Therapeutics position peaked at $3.95M in Q3 2025.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.